Literature DB >> 12947006

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Faith E Davies1, Ann M Dring, Cheng Li, Andrew C Rawstron, Masood A Shammas, Sheila M O'Connor, James A L Fenton, Teru Hideshima, Dharminder Chauhan, Isabella T Tai, Elizabeth Robinson, Daniel Auclair, Karen Rees, David Gonzalez, A John Ashcroft, Ranjit Dasgupta, Constantine Mitsiades, Nicholas Mitsiades, Lan B Chen, Wing H Wong, Nikhil C Munshi, Gareth J Morgan, Kenneth C Anderson.   

Abstract

To define specific pathways important in the multistep transformation process of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) and multiple myeloma (MM), we have applied microarray analysis to PCs from 5 healthy donors (N), 7 patients with MGUS, and 24 patients with newly diagnosed MM. Unsupervised hierarchical clustering using 125 genes with a large variation across all samples defined 2 groups: N and MGUS/MM. Supervised analysis identified 263 genes differentially expressed between N and MGUS and 380 genes differentially expressed between N and MM, 197 of which were also differentially regulated between N and MGUS. Only 74 genes were differentially expressed between MGUS and MM samples, indicating that the differences between MGUS and MM are smaller than those between N and MM or N and MGUS. Differentially expressed genes included oncogenes/tumor-suppressor genes (LAF4, RB1, and disabled homolog 2), cell-signaling genes (RAS family members, B-cell signaling and NF-kappaB genes), DNA-binding and transcription-factor genes (XBP1, zinc finger proteins, forkhead box, and ring finger proteins), and developmental genes (WNT and SHH pathways). Understanding the molecular pathogenesis of MM by gene expression profiling has demonstrated sequential genetic changes from N to malignant PCs and highlighted important pathways involved in the transformation of MGUS to MM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947006     DOI: 10.1182/blood-2003-01-0016

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Primary sclerosing cholangitis in association with multiple myeloma.

Authors:  Nasrollah Ahmadpour; Matthew Downey; Elizabeth Frauenhoffer; Thomas Riley; Ian R Schreibman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

3.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

4.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

5.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

6.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

7.  In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authors:  Dharminder Chauhan; Arghya Ray; Kristina Viktorsson; Jack Spira; Claudia Paba-Prada; Nikhil Munshi; Paul Richardson; Rolf Lewensohn; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-04-12       Impact factor: 12.531

8.  Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Bryan Ciccarelli; Paul G Richardson; Michael A Palladino; Kenneth C Anderson
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

9.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.

Authors:  Masahisa Jinushi; Matthew Vanneman; Nikhil C Munshi; Yu-Tzu Tai; Rao H Prabhala; Jerome Ritz; Donna Neuberg; Kenneth C Anderson; Daniel Ruben Carrasco; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-17       Impact factor: 11.205

10.  G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Authors:  Venugopalan Cheriyath; Keith B Glaser; Jeffrey F Waring; Rachid Baz; Mohamad A Hussein; Ernest C Borden
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.